Standard BioTools Inc. SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account
Standard BioTools Inc. (LAB) reported SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account of -$27.89 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Notes › Valuation and Qualifying Accounts
us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts · last filed 2018-03-08
- Standard BioTools Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to other account for fiscal 2017 was -$27.89M, a 225.91% decline from fiscal 2016.
- Standard BioTools Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to other account for fiscal 2016 was $22.15M, a 58.54% increase from fiscal 2015.
- Standard BioTools Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to other account for fiscal 2015 was $13.97M, a 0.56% increase from fiscal 2014.
- Standard BioTools Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to other account for fiscal 2014 was $13.89M.
| Period end | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 12 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 12 month as first filed |
|---|---|---|
| 2017-12-31 | -$27.89M 10-K · filed 2018-03-08 | |
| 2016-12-31 | $22.15M 10-K · filed 2018-03-08 | |
| 2015-12-31 | $13.97M 10-K · filed 2018-03-08 | $0.00 10-K · filed 2016-02-29 |
| 2014-12-31 | $13.89M 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |